Jupiter Neurosciences Sets 1-for-75 Reverse Split to Avoid Nasdaq Delisting
JUNS is trading near its 52-week low of $0.083 (6.6% below the low) on light trading volume (0.2× avg).
Summary
Jupiter Neurosciences announced a 1-for-75 reverse stock split, the final step in its plan to regain Nasdaq compliance. The ratio falls within the 1:10 to 1:100 range approved by shareholders in June. With shares trading at $0.0778, near the 52-week low, the split will mechanically boost the price to around $5.84, but the underlying financial distress remains severe. The company has a going concern warning, mounting losses, and has relied on dilutive financing. This follows the June proxy seeking approval and the May direct offering that barely kept operations afloat. The split buys time but does not address the cash burn or the need for a viable pipeline.
At the time of this announcement, JUNS was trading at $0.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.08 to $1.84. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.